Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 15/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12336109 | 0.95 | NAMPT (0.59) | NAMPTLMNAL3MBTL1POLB | |
| SCHEMBL12335322 | 0.93 | CYP11B1 (0.63) | NAMPTLMNACYP11B1CYP11B2LRRK2 | |
| SCHEMBL12335060 | 0.91 | NAMPT (0.58) | NAMPTCYP11B1CYP11B2L3MBTL1POLB | |
| SCHEMBL12335447 | 0.91 | NAMPT (0.62) | NAMPTCYP11B1CYP11B2POLB | |
| SCHEMBL12336096 | 0.90 | LMNA (0.61) | NAMPTLMNACYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL12336101 | 0.90 | LRRK2 (0.59) | NAMPTLRRK2L3MBTL1POLB | |
| SCHEMBL12336078 | 0.90 | NAMPT (0.61) | NAMPTLMNACYP11B1CYP11B2POLB | |
| SCHEMBL12335054 | 0.89 | NAMPT (0.59) | NAMPTLRRK2L3MBTL1 | |
| SCHEMBL12335344 | 0.88 | NAMPT (0.61) | NAMPTCYP11B1CYP11B2L3MBTL1POLB | |
| SCHEMBL12334608 | 0.88 | POLB (0.60) | NAMPTLMNACYP11B1CYP11B2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-8912184-B1 | Therapeutic and diagnostic methods | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912184-B1 | Therapeutic and diagnostic methods | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| WO-2011109441-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | NAMPT, NAPRT, NNT | NAMPT 1/4885LMNA 1146/4885CYP11B1 2221/4885 |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | NAMPT 596/4885LMNA 4409/4885CYP11B1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.